— Know what they know.
Not Investment Advice

SRRA NASDAQ

Sierra Oncology, Inc.
1W: +0.1% 1M: +0.4% 3M: +69.8% 1Y: +182.4% 3Y: +149.9% 5Y: +12.7%
$54.99
Last traded 2022-06-30 — delisted
NASDAQ · Healthcare · Biotechnology

Balance Sheet Trends

Total Assets
$109M +1.7% ▲
5Y CAGR: -0.3%
Total Liabilities
$13M +40.3% ▲
5Y CAGR: +11.6%
Shareholders Equity
$96M -2.0% ▼
5Y CAGR: -1.4%
Cash & Investments
$105M +0.7% ▲
5Y CAGR: -0.8%
Total Debt
$853K +123.3% ▲
Net Debt
-$104M -0.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$100M$106M$148M$104M$105M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$100M$106M$148M$104M$105M
Net Receivables$103K$914K$197K$311K$147K
Inventory$0$0$0$0$0
Other Current Assets$1M$2M$2M$2M$2M
Total Current Assets$102M$109M$150M$106M$107M
Property, Plant & Equip.$154K$168K$702K$370K$929K
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$319K$549K$729K$647K$1M
Total Non-Current Assets$473K$717K$1M$1M$2M
Total Assets$102M$109M$151M$107M$109M
— Liabilities —
Accounts Payable$1M$1M$1M$2M$2M
Short-Term Debt$0$0$187K$207K$368K
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$6M$9M$63M$7M$10M
Total Current Liabilities$7M$10M$65M$9M$13M
Long-Term Debt$0$5M$374K$175K$485K
Other Non-Current Liab.$0$0$0$0$0
Total Non-Current Liabilities$0$5M$374K$175K$485K
Total Liabilities$7M$15M$65M$10M$13M
— Equity —
Common Stock$52K$74K$74K$11K$16K
Retained Earnings-$624M-$677M-$766M-$847M-$941M
Accumulated OCI-$275K-$361K-$443K$0$0
Total Stockholders Equity$95M$94M$86M$98M$96M
Total Liabilities & Equity$102M$109M$151M$107M$109M
— Key Metrics —
Total Debt$0$5M$561K$382K$853K
Net Debt-$100M-$101M-$147M-$104M-$104M
Total Investments$0$0$0$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms